Albert C. Koong

Albert C. Koong

Auto-generated profile, based on publicly available information

Albert C. Koong

Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Cancer Cell
Verified
Journal Article
Closed access
JEJanine Terra Erler
Janine Terra Erler
KBKevin L. Bennewith
Kevin L. Bennewith
TCThomas R. Cox
Thomas R. Cox
GLGeorgina Lang
Georgina Lang
DBDemelza Bird
Demelza Bird
AGAmato J. Giaccia
Amato J. Giaccia

7 August 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MTMargaret A. Tempero
Margaret A. Tempero
MMMokenge P. Malafa
Mokenge P. Malafa
MAMahmoud Al-Hawary
Mahmoud Al-Hawary
HAHoracio Asbun
Horacio Asbun
ABAndrew Bain
Andrew Bain
SDSusan Darlow
Susan Darlow
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

15 February 2000 in Genes & Development
Verified
Journal Article
Closed access
PDF file
WZWayne Zundel
Wayne Zundel
CSCornelia Schindler
Cornelia Schindler
DHDaphne Haas-Kogan
Daphne Haas-Kogan
AKAlbert Koong
Albert Koong
FKFiona Kaper
Fiona Kaper
AGAmato J. Giaccia
Amato J. Giaccia
In glioblastoma-derived cell lines, PTEN does not significantly alter apoptotic sensitivity or cause complete inhibition of DNA synthesis. However, in these cell lines PTEN regulates hypoxia- and IGF-1-induced angiogenic gene expression by regulating Akt activation of HIF-1 activity. Restoration of wild-type PTEN to glioblastoma cell lines lacking functional PTEN ablates hypoxia and IGF-1 induction of HIF-1-regulated genes. In addition, Akt activation leads to HIF-1α stabilization, whereas PTEN attenuates hypoxia-mediated HIF-1α stabilization. We propose that loss ofPTEN during malignant progression contributes to tumor expansion through the deregulation of Akt activity and HIF-1-regulated gene expression.

1 November 2000 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
AKAlbert C Koong
Albert C Koong
VMVivek K Mehta
Vivek K Mehta
QLQuynh T Le
Quynh T Le
GFGeorge A Fisher
George A Fisher
DTDavid J Terris
David J Terris
MVMark Vierra
Mark Vierra
Because of the dismal outcomes of conventional therapies for pancreatic carcinomas, we postulated that hypoxia may exist within these tumors. Seven sequential patients with adenocarcinomas of the pancreas consented to intraoperative measurements of tumor oxygenation using the Eppendorf (Hamburg, Germany) polargraphic electrode. All 7 tumors demonstrated significant tumor hypoxia. In contrast, adjacent normal pancreas showed normal oxygenation. Tumor hypoxia exists within pancreatic cancers.

23 December 2014 in Cancer
Verified
Journal Article
Open access
PDF file
JHJoseph M. Herman
Joseph M. Herman
DCDaniel T. Chang
Daniel T. Chang
KGKaryn A. Goodman
Karyn A. Goodman
ADAvani S. Dholakia
Avani S. Dholakia
SRSiva P. Raman
Siva P. Raman
AKAlbert C. Koong
Albert C. Koong
BACKGROUND: This phase 2 multi‐institutional study was designed to determine whether gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single‐fraction SBRT in patients with locally advanced pancreatic cancer (LAPC).METHODS: A total of 49 patients with LAPC received up to 3 doses of GEM (1000 mg/m2) followed by a 1‐week break and SBRT (33.0 gray [Gy] in 5 fractions). After SBRT, patients continued to receive GEM until disease progression or toxicity. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0] and the Radiation Therapy Oncology Group radiation morbidity scoring criteria. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ‐C30) and pancreatic cancer‐specific QLQ‐PAN26 module before SBRT and at 4 weeks and 4 months after SBRT.RESULTS: The median follow‐up was 13.9 months (range, 3.9‐45.2 months). The median age of the patients was 67 years and 84% had tumors of the pancreatic head. Rates of acute and late (primary endpoint) grade ≥2 gastritis, fistula, enteritis, or ulcer toxicities were 2% and 11%, respectively. QLQ‐C30 global quality of life scores remained stable from baseline to after SBRT (67 at baseline, median change of 0 at both follow‐ups; P>.05 for both). Patients reported a significant improvement in pancreatic pain (P = .001) 4 weeks after SBRT on the QLQ‐PAN26 questionnaire. The median plasma carbohydrate antigen 19‐9 (CA 19‐9) level was reduced after SBRT (median time after SBRT, 4.2 weeks; 220 U/mL vs 62 U/mL [P<.001]). The median overall survival was 13.9 months (95% confidence interval, 10.2 months‐16.7 months). Freedom from local disease progression at 1 year was 78%. Four patients (8%) underwent margin‐negative and lymph node‐negative surgical resections.CONCLUSIONS: Fractionated SBRT with GEM results in minimal acute and late gastrointestinal toxicity. Future studies should incorporate SBRT with more aggressive multiagent chemotherapy. Cancer 2015;121:1128–1137. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

1 September 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LRLorenzo Romero-Ramírez
Lorenzo Romero-Ramírez
HCHongbin Cao
Hongbin Cao
DNDaniel Nelson
Daniel Nelson
EHEster Hammond
Ester Hammond
ALAnn-Hwee Lee
Ann-Hwee Lee
AKAlbert C. Koong
Albert C. Koong
Hypoxia within solid tumors is a major determinant of outcome after anticancer therapy. Analysis of gene expression changes during hypoxia indicated that unfolded protein response genes were one of the most robustly induced groups of genes. In this study, we investigated the hypoxic regulation of X-box binding protein (XBP1), a major transcriptional regulator of the unfolded protein response. Hypoxia induced XBP1 at the transcriptional level and activated splicing of its mRNA, resulting in increased levels of activated XBP1 protein. After exposure to hypoxia, apoptosis increased and clonogenic survival decreased in XBP1-deficient cells. Loss of XBP1 severely inhibited tumor growth due to a reduced capacity for these transplanted tumor cells to survive in a hypoxic microenvironment. Taken together, these studies directly implicate XBP1 as an essential survival factor for hypoxic stress and tumor growth.